Risultati per: Terapia antibiotica: breve durata vs. lunga durata

This randomized clinical trial evaluates the efficacy of opt-out care vs opt-in care for people who use tobacco.

This randomized clinical trial of adults with intermediate-risk acute myeloid leukemia explores the optimal therapy for these patients after complete remission.

This 20-year follow-up of a randomized clinical trial reports the long-term associations of early intervention services compared with treatment as usual for individuals with first-episode schizophrenia spectrum disorder.

Tumor Necrosis Factor inhibitors (TNFi), including infliximab and adalimumab, are a mainstay of pediatric Crohn’s disease (PCD) therapy; however, non-response and loss of response is common. As combination therapy with methotrexate may improve response, we performed a multi-center, randomized, double-blind, placebo-controlled pragmatic trial to compare TNFi with oral methotrexate to TNFi monotherapy.

Ricorrendo a globuli bianchi di donatori sani

This randomized clinical trial examines the expulsion rate of intrauterine devices placed between 2 to 4 weeks postpartum compared with standard placement timing at 6 to 8 weeks postpartum.

This platform randomized clinical trial examines the effectiveness of ivermectin at a targeted dose of 600 μg/kg daily compared with placebo for the treatment of early mild to moderate COVID-19.

Ok Aifa rimborsabilità molecola, migliora probabilità guarigione

To the Editor We have several concerns regarding the recent randomized clinical trial about the role of burst stimulation in patients with chronic pain after back surgery.

To the Editor We believe that there are multiple issues that limit the generalizability of the recent randomized clinical trial of spinal cord burst stimulation vs placebo stimulation in patients with chronic radicular pain after lumbar spine surgery.

To the Editor In a recent randomized clinical trial that included patients with chronic radicular pain after spine surgery, Dr Hara and colleagues found no significant difference in back pain–related disability with burst spinal cord stimulation vs placebo. We commend the authors for their avoidance of industry sponsorship, which can introduce bias into interventional pain research. However, we would like to highlight important aspects of this study.

To the Editor As leaders of the American Society of Anesthesiologists, the American Association of Neurological Surgeons, the American Academy of Pain Medicine, the American Society of Pain and Neuroscience, the Congress of Neurological Surgeons, the International Neuromodulation Society, and the North American Neuromodulation Society, we are writing to express our serious concerns about the randomized clinical trial by Dr Hara and colleagues.

To the Editor We believe there are several methodological problems that limit interpretation of the findings of the crossover randomized clinical trial by Dr Hara and colleagues. A fundamental flaw is that patient selection was based on a minimal 2-point reduction in leg pain using a paresthesia trial; a 50% pain reduction from baseline is the commonly used threshold for spinal cord stimulation implantation. This trial considered leg pain intensity, but the primary outcome was disability for back pain. The authors assumed that all patients who responded to paresthesia spinal cord stimulation would respond to burst spinal cord stimulation. Although some of these patients may have met these criteria, the majority may not have, creating heterogeneity. Moreover, the authors did not evaluate the response to the burst trial prior to the crossover period. In the PROCO trial, a positive response to paresthesia spinal cord stimulation led to implantation, but only those responding to 10 kHz were randomized to variable-kilohertz stimulation.

In Reply In our quadruple-blinded, crossover, randomized clinical trial of 50 patients with chronic radicular pain after spine surgery, spinal cord burst stimulation resulted in no significant differences in core outcome measures, including functional disability measured by the Oswestry Disability Index, the Numerical Rating Scale for leg and back pain, quality of life, and physical activity levels, compared with placebo.

Augmentation with aripiprazole or bupropion produced higher remission rates than switching to bupropion.

For achalasia patients with persistent or recurrent symptoms after laparoscopic Heller myotomy (LHM), pneumatic dilation (PD) is the most frequently used treatment. Per-oral endoscopic myotomy (POEM) is increasingly being investigated as rescue therapy. This study aimed to determine the efficacy of POEM versus PD for patients with persistent or recurrent symptoms after LHM.